Mesna
Untreated Adult Acute Lymphoblastic Leukemia
Mayo ClinicSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
74 Active assets in the Untreated Adult Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MERCAPTOPURINE ANHYDROUS Shanxi Bethune Hospital | Phase 4 | A |
Cyclophosphamide The First Affiliated Hospital of Zhengzhou University | Phase 4 | BBB |
METHOTREXATE PETHEMA Foundation | Phase 4 | BBB |
DEXAMETHASONE Shanxi Bethune Hospital | Phase 4 | BBB |
Cytosin-Arabinosid PETHEMA Foundation | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Mesna is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →